Citation Tools

other Versions

Download PDFPDF
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer

Download to a citation manager

Cite this article as:
Bogani G, Coleman RL, Vergote I, et al
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer